Biofilms in Peritoneal Dialysis

Dasgupta, Mrinal; Larabie, M

doi:10.1177/089686080102103s37

Cited by 27 publications

(16 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The existence of biofilms on peritoneal catheters was demonstrated long ago from skinassociated bacteria [65,66]. PD-catheter biofilms are formed by common Gram-positive and Gram-negative bacteria and are frequently associated with clinical peritonitis.…”

Section: Chronic Kidney Disease and Renal Replacement Therapiesmentioning

confidence: 99%

The microbiome in chronic kidney disease patients undergoing hemodialysis and peritoneal dialysis

Simões-Silva

Araújo

Pestana

et al. 2018

Pharmacological Research

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is associated with an imbalanced human microbiome due not only to CKD-associated factors such as uremia, increased inflammation and immunosuppression, but also to pharmacological therapies and dietary restrictions. End-stage renal disease patients require renal replacement therapies commonly in the form of hemodialysis (HD) or peritoneal dialysis (PD). HD implies the existence of a vascular access, such as an arteriovenous fistula/graft or a venous catheter, whereas PD implies a long-term peritoneal catheter and the constant inflow of peritoneal dialysate. Also, dietary adaptations are mandatory in both therapies. This revision explores the impact of HD or PD therapies on human microbiome. HD and PD appear to be associated with different changes in the gut microbiome, for example a decrease in Proteobacteria relative abundance in HD patients and increase in PD patients. Both therapies may also have an impact on the human microbiome beyond the gut, leading to increased relative abundance of specific bacteria in the blood microbiome of HD patients and increased relative abundance of other bacteria in the peritoneal microbiome of PD patients. HD and PD catheter biofilms may also play an important role in the changes observed in these microbiomes. A more interdisciplinary approach is needed to further clarify the role of microbial groups other than bacteria in all body habitats to allow the complete understanding of the impact of HD or PD on the microbiome of CKD patients. Moreover, strategies that promote a healthy balance of the human microbiome on these patients should be explored.

show abstract

Section: Chronic Kidney Disease and Renal Replacement Therapiesmentioning

confidence: 99%

The microbiome in chronic kidney disease patients undergoing hemodialysis and peritoneal dialysis

Simões-Silva

Araújo

Pestana

et al. 2018

Pharmacological Research

View full text Add to dashboard Cite

show abstract

“…Whilst the majority of the literature has attributed morphologic and functional changes of the peritoneal membrane to PD solutions and peritonitis, the PD catheter itself can also induce peritoneal inflammation independently with associated disruption of peritoneal membrane integrity [ 64 , 65 ]. Certainly, the development of biofilm bacterial growth in PD catheters due to skin bacteria [ 66 ] and PD peritonitis episodes [ 67 ] is well acknowledged and can lead to dissemination of bacteria into the PD fluid with resultant peritonitis [ 68 ]. However, there are reports of proinflammatory responses associated with the use of PD catheters independent of bacteria-related biofilm.…”

Section: Clinical Causes Of Inflammation In Peritoneal Dialysis Pamentioning

confidence: 99%

Clinical Causes of Inflammation in Peritoneal Dialysis Patients

Cho

Hawley

Johnson

2014

International Journal of Nephrology

View full text Add to dashboard Cite

Inflammation at both systemic and local intraperitoneal levels commonly affects peritoneal dialysis (PD) patients. Interest in inflammatory markers as targets of therapeutic intervention has been considerable as they are recognised as predictors of poor clinical outcomes. However, prior to embarking on strategies to reduce inflammatory burden, it is of paramount importance to define the underlying processes that drive the chronic active inflammatory status. The present review aims to comprehensively describe clinical causes of inflammation in PD patients to which potential future strategies may be targeted.

show abstract

“…The International Society of Peritoneal Dialysis (ISPD) recommends removal of peritoneal catheter (PC) if there is no improvement after five days on appropriate antibiotic therapy [refractory peritonitis] (13). The primary goal of catheter removal should be peritonitis prevention and peritoneal membrane protection (14). In the first episode, since clinical condition improved, we did not consider the possibility of removing the PC.…”

Section: Discussionmentioning

confidence: 99%

Repeated Burkholderia cepacia Peritonitis in a Patient Undergoing Continuous Ambulatory Peritoneal Dialysis

et al. 2015

West Indian Med J

View full text Add to dashboard Cite

Burkholderia cepacia (B cepacia) is a rare opportunistic pathogen in continuous ambulatory peritoneal dialysis (CAPD) peritonitis. We describe the first case of repeated B cepacia CAPD peritonitis, occurring in an outpatient environment, treated with antimicrobial medication without peritoneal catheter removal. B cepacia may lead to repeat infection, therefore, we should insist on catheter removal during each peritonitis episode.

show abstract

Biofilms in Peritoneal Dialysis

Cited by 27 publications

References 17 publications

The microbiome in chronic kidney disease patients undergoing hemodialysis and peritoneal dialysis

The microbiome in chronic kidney disease patients undergoing hemodialysis and peritoneal dialysis

Clinical Causes of Inflammation in Peritoneal Dialysis Patients

Repeated Burkholderia cepacia Peritonitis in a Patient Undergoing Continuous Ambulatory Peritoneal Dialysis

Contact Info

Product

Resources

About